Skip to content

French National Registry of Rare Peritoneal Surface Malignancies

French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02834169
Acronym
RENAPE
Enrollment
2171
Registered
2016-07-15
Start date
2010-10-31
Completion date
2018-12-31
Last updated
2017-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appendiceal Mucinous Neoplasms, Desmoplastic Small Round Cell Tumor, Diffuse Peritoneal Leiomyomatosis, Peritoneal Mesothelioma, Primary Peritoneal Serous Carcinoma, Psammocarcinoma, Pseudomyxoma Peritonei, Rare Peritoneal Surface Malignancies

Keywords

Rare peritoneal surface malignancies, pseudomyxoma peritonei, peritoneal mesothelioma, desmoplastic small round cell tumor, psammocarcinoma, primary peritoneal serous carcinoma, diffuse peritoneal leiomyomatosis, appendiceal mucinous neoplasms, registry, population-based database

Brief summary

Despite advances in the management of and changes in clinical practice, little is known about the epidemiology, patterns of care and outcomes of rare peritoneal surface malignancies patients in France. In order to better understand the characteristics of rare peritoneal surface malignancies and to evaluate treatment strategies, the RENAPE registry aims at the collection of data from patients presenting with a rare peritoneal surface malignancy in France. Data will be entered prospectively in a specifically designed and secured web database. All RENAPE's centres and physicians are invited to register patients with a rare peritoneal surface malignancy diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focusing on types of rare peritoneal surface malignancies, treatment modalities and patient outcomes (e.g. survival, recurrence), thereby contributing to the better understanding of these rare cancers.

Interventions

OTHERNon interventional

Data collection

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients are eligible if they have a histologically proven rare peritoneal surface malignancy.

Exclusion criteria

* Histological diagnostic of peritoneal surface malignancy not confirmed * Expected clinical follow up data not available

Design outcomes

Primary

MeasureTime frameDescription
Incidence of rare peritoneal surface malignanciesyear 5Collect detailed clinical and histological diagnosis for estimating annual incidence rate

Secondary

MeasureTime frameDescription
Impact of specific treatment strategiesyear 5Collect detailed therapeutic strategies (surgical procedure, chemotherapy, etc.) on patients with rare peritoneal surface malignancies

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026